Key result
The enteric-coated tablet of fenofibric acid demonstrated bioequivalence to the capsule under fasting and fed conditions, indicating higher bioavailability for the enteric-coated formulation.
Why the study?
The study was conducted to compare the pharmacokinetic and safety profiles of two fenofibric acid formulations under fasting and fed conditions.
Does fenofibric acid 110 mg enteric-coated tablet have comparable pharmacokinetics to 135 mg capsule in healthy Korean men?
RCT (n=120)
Open-label
Randomized (1:1 ratio)
No
Does fenofibric acid 110 mg enteric-coated tablet have comparable pharmacokinetics to 135 mg capsule in healthy Korean men?
The 110 mg enteric-coated tablet of fenofibric acid demonstrated higher bioavailability than the 135 mg capsule in healthy volunteers.
Answers are grounded in this paper and cite their sources.
Supports formulation development in healthy volunteers; leaves open clinical efficacy and outcomes in patients.
This study aimed to compare the pharmacokinetic (PK) and safety profiles of 2 fenofibric acid formulations under fasting and fed conditions.The reference was a 135 mg capsule, while the test was a 110 mg enteric-coated tablet.This randomized, open-label, two-sequence, two-period crossover phase 1 clinical trial was conducted in healthy Korean men.Sixty participants were enrolled in each of the fasting and feeding groups.Blood samples were collected 72 hours after drug administration.PK parameters were calculated using a noncompartmental method with Phoenix WinNonlin .A total of 53 and 51 participants from the fasting and feeding groups, respectively, completed the study.The geometric mean ratio and 90% confidence intervals of the maximum concentration (C max ) and area under the concentration-time curve to the last measurable plasma concentration were 0.9195 (0.8795-0.9614) and 0.8630 (0.8472-0.8791) in the fasting study and 1.0926 (1.0102-1.1818)and 0.9998 (0.9675-1.0332) in the fed study, respectively.The time to reach C max of the enteric-coated tablet compared to that of the capsule was extended by 1 and 3 hours under fasting and fed conditions, respectively.In conclusion, enteric-coated tablets have a higher bioavailability than capsules.In addition, the enteric-coated tablet was smaller than the capsule, making it easier for patients to swallow.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2023) conducted an RCT in Healthy volunteers (n=120). Fenofibric acid enteric-coated tablet vs. Fenofibric acid 135 mg capsule was evaluated on Area under the concentration-time curve to the last measurable plasma concentration (AUClast) under fasting conditions (GMR 0.8630, 95% CI 0.8472-0.8791). The enteric-coated tablet of fenofibric acid demonstrated bioequivalence to the capsule under fasting and fed conditions, indicating higher bioavailability for the enteric-coated formulation.
Synapse has enriched 10 related papers. Consider them for comparative context: